osimertinib and Cardiovascular-Diseases

osimertinib has been researched along with Cardiovascular-Diseases* in 2 studies

Other Studies

2 other study(ies) available for osimertinib and Cardiovascular-Diseases

Article	Year
Cardiovascular safety of novel non-small cell lung cancer oncotherapy in a patient treated with novel generations of tyrosine kinase inhibitors. Kardiologia polska, 2018, Volume: 76, Issue:3 Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cardiotonic Agents; Cardiovascular Diseases; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Nebivolol; Piperazines; Protein Kinase Inhibitors; Quinazolines; Ramipril	2018
Cardiac Dysfunction Caused by Osimertinib. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2017, Volume: 12, Issue:10 Topics: Acrylamides; Aged, 80 and over; Aniline Compounds; Cardiovascular Diseases; Female; Humans; Piperazines	2017

Article

Year

Cardiovascular safety of novel non-small cell lung cancer oncotherapy in a patient treated with novel generations of tyrosine kinase inhibitors.

Kardiologia polska, 2018, Volume: 76, Issue:3

Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cardiotonic Agents; Cardiovascular Diseases; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Nebivolol; Piperazines; Protein Kinase Inhibitors; Quinazolines; Ramipril

2018

Cardiac Dysfunction Caused by Osimertinib.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2017, Volume: 12, Issue:10

Topics: Acrylamides; Aged, 80 and over; Aniline Compounds; Cardiovascular Diseases; Female; Humans; Piperazines

2017